{
    "clinical_study": {
        "@rank": "148163", 
        "acronym": "MB-6", 
        "arm_group": [
            {
                "arm_group_label": "MB-6+FOLFOX chemotherapy", 
                "description": "MB-6, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks"
            }, 
            {
                "arm_group_label": "Placebo+FOLFOX chemotherapy", 
                "description": "Placebo, 6 capsules  tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, placebo-controlled multi-center phase\u2162study to evaluate\n      efficacy and safety of oxaliplatin-based chemotherapy plus MB-6(320 mg/capsule, 6 capsules\n      tid) in patients with stage 3 colorectal cancer who underwent surgical excision of their\n      primary tumor."
        }, 
        "brief_title": "A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stage III Colorectal Cancer", 
            "Neutropenia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neutropenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigational new drug, MB-6, in the proposed clinical trial is to be used as an\n      adjuvant therapy for metastatic colorectal cancer patients. All of six extracts have been\n      used in human with a long history, and many literatures reported the medicinal use either\n      individually or as ingredients of formulations. MB-6 may provide its therapeutic benefits\n      via inhibition of tumor induction or enhancing the efficacy of chemotherapy in colorectal\n      cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men or women 20 years of age or older.\n\n          2. Histologically or cytologically confirmed stage 3 colorectal adenocarcinoma.\n\n          3. Complete resection of the primary tumor without gross or microscopic evidence of\n             residual disease.\n\n          4. No more than 8 weeks have elapsed from the time of surgery and have recovered from\n             the effects.\n\n          5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) < 2 at the time of\n             screening.\n\n          6. Hematological function: ANC\u22651500/mm3, Hemoglobin \u22659.0 g/dL, Platelet count\n             \u2265100000/mm3.\n\n          7. Kidney function:Serum creatinine <2 mg/dL.\n\n          8. Liver function: AST \u22643 times ULN, ALT \u22643 times ULN, Total Bilirubin \u22642 times ULN.\n\n          9. Ability to understand and the willingness to sign a written informed consent document\n             according to institutional guidelines.\n\n         10. Men and women of childbearing potential must agree to employ adequate contraception\n             during the study period.\n\n        Exclusion Criteria:\n\n          1. History of second primary malignancies except for adequately treated basal cell\n             carcinoma of the skin or carcinoma in situ of the cervix.\n\n          2. Systemic chemotherapy, immune therapy or experimental or approved antibodies/proteins\n             (e.g. bevacizumab) administered after surgery and prior to randomization.\n\n          3. Concurrent treatment with any other anticancer therapy.\n\n          4. Radiotherapy \u226414 days prior to randomization.\n\n          5. Any unresolved toxicity > CTC (Common Toxicity Criteria) grade 1 from previous\n             anti-cancer therapy (including radiotherapy) except haematological toxicity and\n             alopecia.\n\n          6. Patients with congestive heart failure, epilepsy, or other significant medical\n             conditions as judged by the investigator.\n\n          7. Contraindications to FOLFOX chemotherapy: peripheral neuropathy NCI CTC >1, liver\n             failure, uncontrolled coronary heart disease, myocardial infarction within the\n             previous 6 months before randomization.\n\n          8. Patient of child-bearing potential is evidently pregnant or is breast feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "A total of 184 patients with stage III colorectal cancer underwent surgery will be\n        recruited into the study for receiving adjuvant therapy over 18 weeks."
            }
        }, 
        "enrollment": {
            "#text": "184", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02135887", 
            "org_study_id": "MB104CLCT02"
        }, 
        "intervention": [
            {
                "arm_group_label": "MB-6+FOLFOX chemotherapy", 
                "description": "6# TID with meal", 
                "intervention_name": "MB-6", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo+FOLFOX chemotherapy", 
                "description": "6# TID with meal", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Stage III Colorectal Cancer", 
            "Grade 4 Neutropenia", 
            "MB-6"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "contact": {
                "email": "lydia.huang@microbio.com.tw", 
                "last_name": "Lydia Huang, B.S.", 
                "phone": "886-2-26558098", 
                "phone_ext": "319"
            }, 
            "facility": {
                "address": {
                    "city": "Taichung", 
                    "country": "Taiwan"
                }, 
                "name": "China Medical Unicersity Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Purpose of This Study is to Evaluate the Effectiveness of MB-6 as Adjuvant Therapy in Reducing Neutropenia When Given Oxaliplatin-based Chemotherapy in Patients With Stage 3 Colorectal Cancer Previously Treated With Surgery.", 
        "overall_contact": {
            "email": "wtchen@mail.cmuh.org.tw", 
            "last_name": "William Chen, M.D.", 
            "phone": "886-4-22052121", 
            "phone_ext": "1638"
        }, 
        "overall_official": {
            "affiliation": "China Medical University Hospital", 
            "last_name": "William Chen, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Taiwan: Ministry of Health and Welfare", 
                "Taiwan: Institutional Review Board", 
                "Taiwan: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary endpoint is the incidence of grade 4 neutropenia during the chemotherapy period, defined as an absolute neutrophil count (ANC) <500/mm3.", 
            "safety_issue": "Yes", 
            "time_frame": "18 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02135887"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the time interval from randomization to the first episode of grade 4 Neutropenia.\nThe analyses for incidence of study event will be conducted using logistic regression model method to adjust for gender and the regimen of chemotherapy (e.g., FOLFOX4 or FOLFOX6).", 
                "measure": "Time to first Grade 4 Neutropenia", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks"
            }, 
            {
                "description": "The febrile neutropenia is defined as an ANC <1000/mm3 and a single temperature \u226538.3 degree of C or a sustained temperature of \u226538.0 degree C for more than one hour.", 
                "measure": "Incidence of Febrile Neutropenia", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks"
            }, 
            {
                "description": "The grade 3 or 4 neutropenia during the chemotherapy period is defined as an absolute neutrophil count (ANC) <1000/mm3.", 
                "measure": "Incidence of Grade 3 or 4 Neutropenia", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Change in Serum Creatinine level", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Health-Related Quality of Life (HRQoL) - QLQ-C30", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Quality of Life -VAS on Fatigue, Constipation, Appetite", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Compliance with Chemotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Increase in Body Weight", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks"
            }
        ], 
        "source": "Microbio Co Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Microbio Co Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}